Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Main Article Content

Brett Hughes
Royal Brisbane and Women’s Hospital and the University of Queensland, Brisbane, Australia

Jean-Jacques Grob
Samantha Bowyer
Fiona Day
Rahul Ladwa
Brian Stein
Eva Muñoz-Couselo
Nicole Basset-Seguin
Alexander Guminski
Laurent Mortier
Axel Hauschild
Michael Migden
Chrysalyne Schmults
Suk-Young Yoo
Jocelyn Booth
Frank Seebach
Israel Lowy
Matthew Fury
Danny Rischin

Keywords

cemiplimab

References

1. Waldman A et al. Hematol Oncol Clin North Am. 2019;33:1–12.

2. Que SKT et al. J Am Acad Dermatol. 2018;78:237–247.

3. Stratigos AJ et al. Eur J Cancer. 2020;128:60–82.

4. Sunshine J et al. Curr Opin Pharmacol. 2015;23:32–38.

5. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

6. Migden MR et al. Lancet Oncol. 2020;21:294–305.

7. Migden MR et al. N Engl J Med. 2018;379:341–351.

8. Rischin D et al. J Immunother Cancer. 2021;9.

9. Rischin D et al. J Immunother Cancer. 2020;8.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.175

Article Details

How to Cite
[1]
Hughes, B., Grob, J.-J. , Bowyer, S., Day, F. , Ladwa, R., Stein, B. , Muñoz-Couselo, E., Basset-Seguin, N., Guminski, A. , Mortier, L. , Hauschild, A. , Migden, M. , Schmults, C. , Yoo, S.-Y., Booth, J. , Seebach, F. , Lowy, I. , Fury, M. and Rischin, D. 2023. Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s175. DOI:https://doi.org/10.25251/skin.7.supp.175.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>